Status:
RECRUITING
Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer
Lead Sponsor:
Hanneke W. M. van Laarhoven
Collaborating Sponsors:
Amsterdam UMC
Conditions:
Cardiovascular Diseases
Arterial Thrombosis
Eligibility:
All Genders
50+ years
Brief Summary
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and are now approved for various types of cancer. The most common side effects of ICI are immune-related adverse events which ca...
Eligibility Criteria
Inclusion
- Patients with confirmed diagnosis of the following tumor types, any stage: esophageal, gastric or junction cancer, colorectal cancer, non-small cell lung carcinoma, melanoma, renal cell carcinoma
- Prior to start of new therapy (i.e. immune checkpoint inhibitor, chemotherapy or follow-up in case of esophageal cancer)
- Age ≥ 50 years
Exclusion
- ICI therapy in previous 12 months
- Suspected or confirmed viral, fungal, or bacterial infectious disease
- Use of immunosuppressive therapy prior to ICI start
- Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m2
- Known allergy to iodinated contrast agents
- Atrial fibrillation
Key Trial Info
Start Date :
January 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
214 Patients enrolled
Trial Details
Trial ID
NCT06519292
Start Date
January 25 2023
End Date
December 31 2025
Last Update
May 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam UMC
Amsterdam, North Holland, Netherlands, 1105AZ